Abbisko Therapeutics, a Shanghai-based biopharmaceutical firm, announced on Friday the completion of a Series D funding round at $123 million to advance the startup’s clinical programmes and to expand its portfolio in the discovery and preclinical development stages.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
